ESMO Congress 2025: Abstracts

The abstract submission is now open!

Submit your abstract 

Abstract submission deadlines

Abstract submission categories

• Basic science
• Biliary tract cancer, incl. cholangiocarcinoma
• Biomarkers and translational research (agnostic)
• Breast cancer, early stage
• Breast cancer, locally advanced
• Breast cancer, metastatic
• CNS tumours
• Colorectal cancer
• Developmental therapeutics
• Endocrine tumours
• Germ cell (testicular) cancer and penile cancer
• Gynaecological cancers
• Haematological malignancies
• Head and neck cancer, excluding thyroid
• Hepatocellular carcinoma (HCC)
• Investigational immunotherapy
• Melanoma and other skin tumours
• Miscellaneous
• Neuroendocrine tumours
• New diagnostic tools
• NSCLC, early stage
• NSCLC, locally advanced
• NSCLC, metastatic
• Oesophagogastric cancer 
• Palliative care
• Pancreatic cancer
• Policy
• Prostate cancer
• Psycho-oncology
• Renal cancer
• Sarcoma
• SCLC
• Supportive care
• Thoracic malignancies, other
• Thyroid cancer
• Tumour biology and pathology
• Urothelial cancer
• *Cancer Nursing: Advance care planning and palliative care
• *Cancer Nursing: eHealth and digital innovations
• *Cancer Nursing: Health promotion, prevention and screening
• *Cancer Nursing: Leadership and educational issues in cancer nursing
• *Cancer Nursing: Precision health
• *Cancer Nursing: Rehabilitation and survivorship care
• *Cancer Nursing: Symptom management

*Abstracts may also be submitted to the Cancer nursing track. Submissions in these categories will be reviewed by the European Oncology Nursing Society (EONS) Scientific Committee for selection and presentation in the EONS cancer nursing programme. Unless otherwise stated, submissions in the Cancer nursing categories must follow all regular ESMO Congress 2025 submission regulations and guidelines.

Late-breaking abstracts (LBAs)

Late-breaking abstracts may be submitted for high quality, new research findings from prospective interventional clinical trials or observational series (large real world data sets) or novel technologies with major implications for clinical practice and/or understanding and targeting of disease processes. 

The final late-breaking abstract deadline of 9 September 2025 is under no circumstances to be considered as an extension of the general submission deadline.

Outcome notifications

Outcome notifications of regular abstracts are expected to be made available to first authors and submitters between 16 and 18 July 2025.

Outcome notifications of pre-accepted, full LBAs are expected to be made available to first authors and submitters between 16 and 18 September 2025.

Abstract presenter registration

The presenting author or the designated replacement presenter must be registered by 1 October 2025. Should the Presenter (or designated replacement presenter) not be registered by the given deadline, the abstract will be excluded from presentation in the ESMO Congress 2025 programme, and removed from the online programme and publication in the ESMO Congress 2025 Abstract Book.

Information for presenters

Detailed instructions for the preparation of slide presentations and posters/ePosters will be made available on the ESMO website by end July 2025 in the “Information for Presenters” section.

Titles of accepted regular abstracts are expected to be made available online in the “Programme” section, by 25 July 2025.

Titles of accepted regular abstracts are expected to be made available online in the “Programme” section, by 20 September 2025.

Presentation and publication of accepted abstracts

The ESMO Congress 2025 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

• Presidential Symposium – Oral presentations by authors presenting cutting-edge and significant clinical practice-changing studies, followed by expert discussion and perspectives.

• Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.

• Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.

• Poster – Paper poster presentation for review and discussion onsite. Presenting authors must attend the Congress in person to represent their work. Preparation of an e-Poster file is also mandatory for inclusion in the Congress Virtual Platform and onsite digital screens.

• E-Poster – Electronic poster in PDF format for inclusion in the Congress Virtual Platform and onsite digital screens. Presenting authors of ePosters are not required to attend the Congress in person to represent their work. Paper posters are not to be prepared, and poster boards will not be provided.

All accepted abstracts, will be published online in the ESMO Congress 2025 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.

Publication schedule for accepted abstracts

Details regarding the publication of accepted abstracts are available here.

ESMO Merit Travel Grants

A limited number of ESMO Merit Travel Grants to the ESMO Congress 2025 are available, upon application, to first authors (= presenters) who submit abstracts considered to be deserving of recognition. Candidates must be ESMO Members under the age of 40. Selection will be made by the ESMO Congress 2025 Scientific Committee on a competitive basis from among the accepted abstracts.